Source:http://linkedlifedata.com/resource/pubmed/id/15304395
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
13
|
| pubmed:dateCreated |
2004-12-6
|
| pubmed:abstractText |
We report the outcomes after reduced-intensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n = 41; high-grade NHL [HG-NHL], n = 37; mantle cell lymphoma [MCL], n = 10). Thirty-seven patients had previously received autografts, and 21 were in complete remission (CR) at transplantation. Conditioning therapy consisted of alemtuzumab, fludarabine, and melphalan. Sixty-five patients received peripheral blood stem cells (PBSCs) from HLA-identical siblings, and 23 received bone marrow (BM) from matched unrelated donors. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporin A. Grade III-IV acute GVHD developed in 4 patients, and chronic GVHD developed in 6 patients. With a median follow-up of 36 months (range, 18-60 months), the actuarial overall survival (OS) rates at 3 years were 34% for HG-NHL, 60% for MCL, and 73% for LG-NHL (P < .001). The 100-day and 3-year transplant-related mortality (TRM) rates for patients with LG-NHL were 2% and 11%, respectively, and were better (P = .01) than they were for patients with HG-NHL (27% and 38%, respectively). The actuarial current progression-free survival (PFS) rate at 3 years, including the rate for patients who achieved remission after donor lymphocyte infusion (DLI) for progression, was 65% for LG-NHL, 50% for MCL, and 34% for HG-NHL (P = .002). Twenty-one patients underwent DLI for matched related donor (MD)-persistent disease or relapse, and 15 underwent DLI for mixed hematopoietic chimerism. Patients who experienced relapses of LG-NHL and chronic lymphocytic leukemia (CLL) achieved excellent PFS with extremely low TRM and GVHD, even when matched related donors were unavailable.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ChopraRajeshR,
pubmed-author:CookGordonG,
pubmed-author:CraddockCharlesC,
pubmed-author:GoldstoneAnthonyA,
pubmed-author:HattonChristopherC,
pubmed-author:HunterAnneA,
pubmed-author:LinchDavidD,
pubmed-author:MackinnonStephenS,
pubmed-author:MahendraPremP,
pubmed-author:MilliganDonaldD,
pubmed-author:MorrisEmmaE,
pubmed-author:ParkerAnneA,
pubmed-author:PeggsKarlK,
pubmed-author:ScheySteveS,
pubmed-author:SmithGraeme MurrayGM,
pubmed-author:ThomsonKirstyK,
pubmed-author:TigheJaneJ
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
104
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3865-71
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15304395-Actuarial Analysis,
pubmed-meshheading:15304395-Adult,
pubmed-meshheading:15304395-Aged,
pubmed-meshheading:15304395-Antibodies, Monoclonal,
pubmed-meshheading:15304395-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15304395-Antibodies, Neoplasm,
pubmed-meshheading:15304395-Antineoplastic Agents,
pubmed-meshheading:15304395-Bone Marrow Transplantation,
pubmed-meshheading:15304395-Combined Modality Therapy,
pubmed-meshheading:15304395-Female,
pubmed-meshheading:15304395-Graft vs Host Disease,
pubmed-meshheading:15304395-Humans,
pubmed-meshheading:15304395-Lymphoma, Non-Hodgkin,
pubmed-meshheading:15304395-Male,
pubmed-meshheading:15304395-Middle Aged,
pubmed-meshheading:15304395-Recurrence,
pubmed-meshheading:15304395-Stem Cell Transplantation,
pubmed-meshheading:15304395-Survival Analysis,
pubmed-meshheading:15304395-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
|
| pubmed:affiliation |
Department of Haematology, Royal Free and University College Hospitals Medical School, 98 Chenies Mews, London WC1E 6HX, United Kingdom. emma.morris@ic.ac.uk
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|